Skip to main content
Fig. 3 | BMC Pediatrics

Fig. 3

From: Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

Fig. 3

Percentage of participants with solicited local and general adverse events, post-each dose (total vaccinated cohort). Group Var-HSA, participants receiving varicella vaccine produced without HSA (human albumin serum); Group Var + HSA, participants receiving varicella vaccine containing HSA. Note: Error bars represent 95% confidence intervals. Grade 3 adverse events were defined as: cried when limb was moved/spontaneously painful for pain; diameter > 20 mm for swelling/redness; temperature > 39.5 °C for fever; > 150 lesions for varicella-like rash; prevented normal, everyday activities and leading to seeking medical advice (all other events). *Two grade 3 varicella-like rashes were reported in this study, both of which were following dose 1 in the Var + HSA group

Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us